From Bench-Based PhD Project to First-in-Man Use of ?3 Adrenergic Agonist in Patients with Treatment-Resistant Decompensated Congestive Heart Failure - 03/08/17
Doi : 10.1016/j.hlc.2017.06.209
N. Fry 2, ⁎, C. Liu 2, A. Garcia 2, G. Karimi Galougahi 2, 4, E. Hamilton 2, J. Harris 3, G. Nelson 1, 3, D. Whalley 1, 3, H. Bundgaard 5, H. Rasmussen 1, 2, 3
1 Royal North Shore Hospital, Sydney, Australia
2 North Shore Heart Research Group, Kolling Institute of Medical Research, Sydney, Australia
3 North Shore Private Hospital, Sydney, Australia
4 Columbia University Medical Centre, New York, USA
5 The Heart Centre, Rigshospitalet, Copenhagen, Denmark
⁎Corresponding author.
Il testo completo di questo articolo è disponibile in PDF.
© 2017
Pubblicato da Elsevier Masson SAS.
Vol 26 - N° S2
P. S134 - 2017 Ritorno al numero
Articolo precedente
- Fitness and Fatness Are Associated with Better Clinical Outcomes in Patients with Heart Failure
- A. Maiorana, L. Naylor, O.G. Driscoll, L. Dembo, S. Dongelmans, D. Thijssen, D. Green
- Genetic Inhibition of Galectin-3 Suppressed Cardiac Fibrosis and Improved Function in a Mouse Model of Dilated Cardiomyopathy
- M. Nguyen, H. Kiriazis, Z. Thomas, Y. Su, X. Gao, J. Sadoshima, J. McMullen, X. Du
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?